Please login to read the full text of the article.
If you have no account yet, please register now.
Posted on
Previous Article
« Promising results in uric acid-lowering in gout patients with a new xanthine oxidase inhibitor Next Article
Sequential rituximab after belimumab does not improve disease control in SLE »
« Promising results in uric acid-lowering in gout patients with a new xanthine oxidase inhibitor Next Article
Sequential rituximab after belimumab does not improve disease control in SLE »
Table of Contents: ACR 2021
Featured articles
Late-Breaking Abstracts
Vaccine booster improves immune response in patients treated with rituximab
IL-17 inhibition showing efficacy in GCA in phase 2 trials
Spotlight on Rheumatoid Arthritis
Cycling JAK inhibitors shows similar effectiveness to switching to a bDMARD in difficult-to-treat RA
Pre-existing heart failure affects safety of hydroxychloroquine in RA patients
Patients with RA-associated interstitial lung disease benefit from antifibrotic agent
Ultra-low dosing of rituximab in RA is a viable treatment option
Kidney disease and hydroxychloroquine dose are risk factors for developing retinopathy
More pros than cons for the use of statins in RA
Psoriatic Arthritis: Novel Developments
Selective IL-23 inhibition: a new option in active PsA
Ustekinumab: highly efficacious in PSA independent of methotrexate
COVID-19: What You Need to Know
Vaccinated rheumatic patients carry increased risk for COVID-19 breakthrough infections
B-cell depleting medication increases COVID-19 breakthrough infection outcome risk
COVID-19 mRNA vaccine safe and tolerable in adults with autoimmune disease
SLE Treatment: What Is New
Iberdomide: an upcoming new treatment possibility in lupus erythematosus
Sequential rituximab after belimumab does not improve disease control in SLE
Lupus patients less protected by COVID-19 vaccine
Late-Breaking Posters
Promising results in uric acid-lowering in gout patients with a new xanthine oxidase inhibitor
Laboratory and clinical signs 24h after hospitalisation predict MIS-C in children
Related Articles


February 3, 2022
PROTECTing renal transplant recipients from uncontrolled gout
© 2021 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy